Acrivon Therapeutics, INC Form 4 insider transactions

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, reports the disposal of shares to cover tax obligations and disclaims beneficial ownership of shares held by her spouse, the company's CEO.

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, disposed of 368 shares to cover tax obligations upon vesting of restricted stock units.

Chief Development Officer Erick Gamelin of Acrivon Therapeutics reports disposing of 402 shares to cover tax obligations upon vesting of restricted stock units.

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports the disposal of 613 common stock shares to cover tax withholding requirements.

Peter Blume-Jensen, CEO of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 558 common stock shares to cover tax obligations upon vesting of restricted stock units.

RA Capital Management, L.P. and affiliated entities acquired 3,530,000 shares of Acrivon Therapeutics at $8.50 per share, increasing their total holdings.

Perceptive Advisors LLC, along with related entities, increased its holdings in Acrivon Therapeutics by purchasing 2,353,000 shares of common stock at $8.50 per share on April 11, 2024.

Director Santhosh Palani of Acrivon Therapeutics reports the acquisition of stock options.